


OKLAHOMA NEPHROLOGY ASSOCIATES

B.J. Matter, M.D.
Dennis R. Mask, M.D.
Anthony Czerwinski, M.D.

Matthew Thigpen, P.A.
Donna Casselman, P.A.

June 3, 1985



U.S. Nuclear Regulatory Commission
Region IV
Materials Licensing Branch
Suite 1000
Arlington, Texas 75012

RE: License No. 35-23173-01


Gentlemen:

Please amend the above-referenced license to add Anthony W. Czerwinski, M.D., as an authorized. Documentation of training and experience for Dr. Czerwinski is enclosed.

Also enclosed is a check for \$120.00.

If you have any questions, please contact the undersigned for assistance.

Sincerely,


B.J. Matter, M.D.

cc: Health Physics Services, Inc.

BJM/kg

Applicant	
Check No.	5929
Amount/Fee Category	\$120.00 - 70
Type of Fee	Amendment
Date Check Rec'd	6/13/85
Received By	Jacques

RECEIVED BY LFMD	
Date	6/13/85
Log	June Pg 1. IV
By	Jacques
Orig. To	
Action Compl	6/18/85

By	
Log	
Date	
Received By LFMD	

U.S. NRC
FEE MGMT. BRANCH

85 JUN 13 AM 1:48

RECEIVED

460666

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

Anthony W. Czerwinski

2. STATE OR TERRITORY IN
WHICH LICENSED TO
PRACTICE MEDICINE
OK & MO

3. CERTIFICATION

SPECIALTY BOARD
ACATEGORY
BMONTH AND YEAR CERTIFIED
CInt. Medicine
Nephrology

1972,

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING
ALOCATION AND DATE(S) OF TRAINING
B

TYPE AND LENGTH OF TRAINING

LECTURE/
LABORATORY
COURSES
(Hours)
CSUPERVISED
LABORATORY
EXPERIENCE
(Hours)
Da. RADIATION PHYSICS AND
INSTRUMENTATIONBone Densitometry Workshop
fully meeting the duration and
content for such instruction as
criteria listed in USNRC Policy
and Guidance Directive FC83-24;
Licensing the Lixiscope and Bone
Mineral Analyzer for Human Use,
dated

2 hours

b. RADIATION PROTECTION

2 hours

c. MATHEMATICS PERTAINING TO
THE USE AND MEASUREMENT
OF RADIOACTIVITY

Same as above

1 hour

d. RADIATION BIOLOGY

Same as, above

3 hours

e. Principles of Photon
Absorptionmetry, measure-
ments, and instrumentation

Same as above

2 hours

1.5 hours

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Anthony W. Czerwinski

STREET ADDRESS

4312 Classen

CITY

Oklahoma City

STATE

OK

ZIP CODE

73118

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

- 1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

TYPE	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
	DIAGNOSIS OF THYROID FUNCTION		<p>*Dr. Czerwinski participated in a two day bone densitometry workshop. During the workshop, five (5) subjects were given complete clinical bone mineral analyses under the direction of a physician, license by the State of # 9-3574 (4/30/89), for the use of bone mineral analyser. See the attached certificate of training.</p> <p><i>Not attached</i></p>
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
5	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
ER	Bone Densitometer	5 *	
5	DETECTION OF THROMBOSIS		
	THYROID IMAGING		
	EYE TUMOR LOCALIZATION		
	PANCREAS IMAGING		
9	CISTERNOGRAPHY		
3	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
	BRAIN IMAGING		
	CARDIAC IMAGING		
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING		
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		

460666

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA		
	TREATMENT OF HYPERTHYROIDISM		
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

6 hours - April 19 and 20, 1985

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

David M. Player, M.D.

b. NAME OF INSTITUTION

Beta Diagnostics, Inc.

c. MAILING ADDRESS

7540 Louis Pasteur Drive, Suite 100

d. CITY

San Antonio, Texas 78229

e. MATERIALS LICENSE NUMBER(S)

Texas License # 9-3574

5. PRECEPTOR'S SIGNATURE

David M. Player MD

6. PRECEPTOR'S NAME (Please type or print)

David M. Player

7. DATE

April 26, 1985

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		
1. B. J. Matter, M.D.	3. License number	35-23173-01
2. 4312 Classen Boulevard Oklahoma City, Oklahoma 73118	4. Expiration date	May 31, 1990
	5. Docket or Reference No.	030-20339
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Iodine-125	A. Sealed sources (AECL Model C-235 or Model C-236; Amersham Model IMC-4040)	A. Not to exceed 400 millicuries per source
9. Authorized use:		
A. For use in Nordland Corporation Model N2740 bone scanner for medical diagnostic bone scanning.		

CONDITIONS

10. Licensed material shall be used only at 4312 Classen Boulevard, Oklahoma City, Oklahoma.

~~85607234132~~
3pp.

MATERIALS LICENSE
SUPPLEMENTARY SHEETLicense number
35-23173-01Docket or Reference number
030-20339

11. The licensee shall comply with the provisions of Title 10, Chapter i, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. Licensed material shall be used by, or under the supervision of, B. J. Matter, M.D.
13. Sealed sources containing licensed material shall not be opened.
14. A. (1) Each sealed source containing licensed material, other than hydrogen-3, with a half-life greater than 30 days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed 6 months. In the absence of a certificate from a transferor indicating that a test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.
(2) The periodic leak test required by this condition does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within 6 months prior to the date of use or transfer.
- B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.
- C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the test with the U. S. Nuclear Regulatory Commission, Region IV, 611 Ryan Plaza Dr., Suite 1000, Arlington, Texas 76011, describing the equipment involved, the test results, and the corrective action taken.

MATERIALS LICENSE
SUPPLEMENTARY SHEETLicense number
35-23173-01
Docket or Reference number
030-20339

14. (continued)

- D. The licensee is authorized to collect leak test samples in accordance with the procedures described in the licensee's letter dated April 26, 1985, for analysis by Beta Diagnostic Company. Alternatively, leak test samples may be collected and/or analyzed by other persons specifically authorized by the Commission or an Agreement State to perform such services.
15. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated April 1, 1985, and letter dated April 26, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAY 21 1985By AL Cain
Nuclear Materials Safety Section
Region IV
Arlington, Texas 76011